Skip to main content

Advertisement

SpringerLink
Log in

Effectiveness of the addition of the brain region to the FDG-PET/CT imaging area in patients with suspected or diagnosed lung cancer

  • ONCOLOGY IMAGING
  • Published:
La radiologia medica Aims and scope Submit manuscript

Abstract

Purpose

We aimed to evaluate the effectiveness of the brain region imaging in FDG-PET/CT scanning of patients with suspected or diagnosed lung cancer.

Materials and methods

We performed the study retrospectively on the medical charts of 427 patients. We divided the FDG-PET/CT field of view (FOV) into four major imaging regions: brain, head–neck, abdomen and pelvis. Metastatic findings on these regions were checked and determined the potential of these findings to affect the chemotherapy or radiotherapy protocol or surgical management. If metastatic findings had a potential to modify these parameters, we named this situation as “clinical contribution”. Considering the number of bed positions of these regions, we calculated the clinical contribution of each region and named as “effective clinical contribution”. Then, we calculated the metastatic findings, clinical contribution, and effective clinical contribution ratios.

Results

We found different brain metastasis ratios for lung cancer, solitary pulmonary mass (SPM), and solitary pulmonary nodule (SPN) groups (8.7, 2.8 and 0.9 %, respectively). In addition, the clinical contribution and effective clinical contribution ratios in the brain region for these three groups were 6.4, 2.8, 0.0 and 6.4, 2.8, 0.0 %, respectively. The highest metastatic findings (30.6 %) and clinical contribution (9.8 %) ratios were found in the abdomen region of the lung cancer group. However, the highest effective clinical contribution ratio (6.8 %) was found in the brain region within the same group.

Conclusions

The addition of the brain region to the limited whole-body FOV in FDG-PET/CT scanning seems to be effective in the lung cancer and SPM groups, but not in the SPN group.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Delbeke D, Coleman RE, Guiberteau MJ et al (2006) Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med 47:885–895

    PubMed  Google Scholar 

  2. Avril N (2004) GLUT1 expression in tissue and (18) F-FDG uptake. J Nucl Med 45:930–932

    CAS  PubMed  Google Scholar 

  3. Abikhzer G, Alabed YZ, Azoulay L et al (2011) Altered hepatic metabolic activity in patients with hepatic steatosis on FDG PET/CT. Am J Roentgenol 196:176–180

    Article  Google Scholar 

  4. Boellaard R, O’Doherty MJ, Weber WA et al (2010) FDG PET and PET/CT: EANM procedure guidelines for tumor PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 37:181–200

    Article  PubMed Central  PubMed  Google Scholar 

  5. ACR-SPR practice guideline for performing FDG-PET/CT in oncology. American College of Radiology Web site. http://www.acr.org/~/media/71B746780F934F6D8A1BA5CCA5167EDB.pdf Accessed 07 Jan 2014

  6. Lee HY, Lee KS, Kim BT et al (2009) Diagnostic efficacy of PET/CT plus brain MR imaging for detection of extrathoracic metastases in patients with lung adenocarcinoma. J Korean Med Sci 24:1132–1138

    Article  PubMed Central  PubMed  Google Scholar 

  7. Sebro R, Mari-Aparici C, Hernandez-Pampaloni M (2013) Value of true whole-body FDG-PET/CT scanning protocol in oncology: optimization of its use based on primary diagnosis. Acta Radiol 54:534–539

    Article  PubMed  Google Scholar 

  8. Bochev P, Klisarova A, Kaprelyan A et al (2012) Brain metastases detectability of routine whole-body (18)F-FDG PET and low dose CT scanning in 2502 asymptomatic patients with solid extracranial tumors. Hell J Nucl Med 15:125–129

    PubMed  Google Scholar 

  9. Kitajima K, Nakamoto Y, Okizuka H et al (2008) Accuracy of whole-body FDG-PET/CT for detecting brain metastases from non-central nervous system tumors. Ann Nucl Med 22:595–602

    Article  PubMed  Google Scholar 

  10. Osman MM, Chaar BT, Muzaffar R et al (2010) 18F-FDG PET/CT of patients with cancer: comparison of whole-body and limited whole-body technique. AJR Am J Roentgenol 195:1397–1403

    Article  PubMed  Google Scholar 

  11. Tasdemir B, Dostbil Z, Inal A et al (2014) Evaluation of clinical contributions provided by addition of the brain, calvarium, and scalp to the limited whole-body imaging area in FDG-PET/CT tumor imaging. Biomed Res Int 2014:129683. doi:10.1155/2014/129683 Epub 2014 Jun 16

    Article  PubMed Central  PubMed  Google Scholar 

  12. Abdelmalik AG, Alenezi S, Muzaffar R et al (2013) The incremental added value of including the head in (18)F-FDG PET/CT imaging for cancer patients. Front Oncol 3:71

    Article  PubMed Central  PubMed  Google Scholar 

  13. Salvatore B, Caprio MG, Fonti R et al (2014) Is 2-deoxy-2-[(18)F]fluoro-d-glucose PET/CT acquisition from the upper thigh to the vertex of skull useful in oncological patients? Transl Med UniSa 19(11):34–38

    Google Scholar 

  14. Huston SF, Abdelmalik AG, Nguyen NC et al (2010) Whole-body 18F-FDG PET/CT: the need for a standardized field of view–a referring-physician aid. J Nucl Med Technol 38:123–127

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Faculty of Medicine, Dicle University, 21280, Diyarbakir, Turkey

    Bekir Tasdemir & Zeki Dostbil

  2. Department of Medical Oncology, Faculty of Medicine, Dicle University, Diyarbakir, Turkey

    Zuhat Urakci

  3. Department of Nuclear Medicine, Faculty of Medicine, İzmir University, Izmir, Turkey

    Kemal Unal

  4. Department of Nuclear Medicine, Elazig Training and Research Hospital, Elazig, Turkey

    F. Selcuk Simsek

  5. Department of Radiation Oncology, Faculty of Medicine, Dicle University, Diyarbakir, Turkey

    Fatma Teke

  6. Department of Radiology, Faculty of Medicine, Dicle University, Diyarbakir, Turkey

    Cemil Goya

Authors
  1. Bekir Tasdemir
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zuhat Urakci
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zeki Dostbil
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kemal Unal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Selcuk Simsek
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fatma Teke
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Cemil Goya
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bekir Tasdemir.

Ethics declarations

Conflict of interest

“The authors declare that they have no financial relationship with any organization related to the research.” The authors declare no conflict of interest.

Ethical approval

“Prior to the study, we obtained ethical approval from the institutional ethics committee and all study protocols were approved by the committee.”

Informed consent

“As the study is retrospective, we did not use any informed consent form.”

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tasdemir, B., Urakci, Z., Dostbil, Z. et al. Effectiveness of the addition of the brain region to the FDG-PET/CT imaging area in patients with suspected or diagnosed lung cancer. Radiol med 121, 218–224 (2016). https://doi.org/10.1007/s11547-015-0597-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11547-015-0597-y

Keywords

Search

Navigation